EVOMMUNE INC (EVMN)
Health Care · Clinical-stage biopharmaceutical / immunology · NYSE
Evommune is a clinical-stage biotechnology company developing novel treatments for inflammatory diseases, currently advancing a pipeline of product candidates including EVO756 and EVO301.
What EVOMMUNE INC does
Evommune is an early-stage clinical-stage biotechnology company developing immunology-focused product candidates. The company's lead programs include EVO756 and EVO301, which are currently in clinical development. Evommune is unprofitable and pre-revenue, requiring additional funding to advance its product candidates toward regulatory approval and potential commercialization.
Themes: immunology, clinical-stage development, biopharmaceutical R&D
Fundamentals
- Price$14.02 as of 2026-08-21 close
- Market cap$509M as of 2026-08-21
- P/En/a negative earnings
- Net margin-606.2% as of 2026-08-24
- ROE-33.5% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+85.7% as of 2026-08-24
- Beta0.42 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How EVMN compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How EVOMMUNE INC looks technically
EVOMMUNE INC (EVMN): a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago.
Trend
7
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $14.90 | $14.90 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 29 calendar days ago — the swings before that are what the structure reading is measured on | 29 sessions |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 20.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30) | 51.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($11.64 to $15.06) — its "stochastic" reading is 70 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 69.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 24 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $33.20 | $33.20 |
|---|---|---|
| From the 52-week high | it is 57.8% below its 52-week high (its highest price of the past year) | -57.8% |
| Above the 52-week low | it is 33.9% above its 52-week low (its lowest price of the past year) | +33.9% |
| Below the 52-week high | it is 57.8% below its highest point of the past year | 57.8% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 18 trading days ago | 18 sessions |
| All-time high | its highest closing price on record is $33.20 (set on 2026-02-10) | $33.20 |
| Given back of the 52-week move | not available for this company yet | n/a |
| From the all-time high | it is 57.8% below its all-time high | -57.8% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $10.47 (set on 2026-07-23) | $10.47 |
| Above the all-time low | it is 33.9% above its all-time low | +33.9% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 63rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9392 between its high and its low — about 6.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9392 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $10.59 and $15.79 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $10.59 – $13.19 – $15.79 |
| Typical daily range (% of price) | its price moves about 6.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.7% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.61× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.3% |
|---|---|---|
| Open gap | it gapped 30.4% below the previous close 38 sessions ago and has not traded back through the level it left behind at 25.18 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -30.4% |
| Gap filled | a 2.5% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 12.4 percentage points (the stock gained 14.7% while the market gained 2.3%) | +12.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 43.6 percentage points (the stock lost 40.5% while the market gained 3.1%) | -43.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 61.5 percentage points (the stock lost 50.5% while the market gained 11.1%) | -61.5% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 2 of the 7 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 7 |
|---|---|---|
| Bearish technical signals | 2 of the 7 technical signals we can compute for it are currently in a bearish state: lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 7 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 32.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -11.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 32% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $20.58 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | -31.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $14.00 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +0.1% |
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Broke out to a new 20-day high · Most volatile (6%+ typical daily range) · Trading below the Ichimoku cloud | Learn: adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.70 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$27.57 range $22.00 – $32.00; median $28.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EVMN
- Consensus EPS estimate-$0.8144 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial success and timing risks for lead candidates EVO756 and EVO301","Substantial capital requirements; company must raise additional funding before generating product revenues","Regulatory approval uncertainty and dependence on establishing adequate safety/efficacy profiles for product candidates"]
What changed in the latest 10-Q
AI-assisted comparison of EVMN's 10-Q filed 2026-05-07 against the prior one filed 2025-12-11.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-07) adds 'migraine' to the list of initial clinical development programs in the Overview section
- Newer filing adds detailed clinical trial timeline information: Phase 2b CSU trial initiated April 2025 with June 2026 results expected
- Newer filing adds: Phase 2b AD trial initiated August 2025 with Q3 2026 results expected
- Newer filing adds: Plan to initiate Phase 2b migraine trial in mid-2026 with 2027 results expected
- Newer filing adds details on EVO301 formulation: 'high concentration of subcutaneous formulation' with manufacturing initiated
- Newer filing adds EVO301 trial details: at least three dosing regimens over 16-week period, commencement planned mid-2027
- Newer filing adds EVO301 expansion indications: 'certain cardiovascular-related inflammatory conditions and food allergy'
- Newer filing updates accumulated deficit figure to $242.8 million as of March 31, 2026
- Removed:
- Older filing (2025-12-11) references 'final prospectus for our initial public offering' and IPO details dated November 5-6, 2025 - removed in newer filing
- Older filing states EVO756 developed 'for the treatment of CSU and AD' - migraine removed from initial development programs statement
- Older filing describes candidates as 'in Phase 2 trials' (more general) vs. newer filing's 'Phase 2 development' with specific phase designations
- Older filing accumulated deficit figure of $192.8 million as of September 30, 2025 - replaced with newer figure
- Reworded:
- Newer filing: 'with initial clinical development programs focusing on chronic spontaneous urticaria ("CSU"), atopic dermatitis ("AD"), migraine and ulcerative colitis ("UC")' vs. older: 'chronic spontaneous urticaria ("CSU"), atopic dermatitis ("AD") and ulcerative colitis ("UC")' - migraine added
- Newer filing: 'in Phase 2 development' vs. older: 'in Phase 2 trials' - terminology change
- Newer filing: 'developing EVO756 for the treatment of CSU, AD and migraine' vs. older: 'for the treatment of CSU and AD' - migraine added
- Older filing includes full IPO prospectus reference in opening paragraph; newer filing references 'Annual Report on Form 10-K for the year ended December 31, 2025' instead
- Notes:
- The older filing was filed shortly after IPO (December 2025) while newer filing is six months later (May 2026), making some differences reflect natural business progression
- Accumulated deficit comparison spans different fiscal periods (September 30, 2025 vs. March 31, 2026)
- Section text appears to be cut off in both versions at the 'Strategic Collaborations' section, limiting full comparison
Risk Factors
- Added:
- Newer filing (2026-05-07) references 'Annual Report on Form 10-K for our fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission, or SEC, on March 5, 2026' as source of Risk Factors
- Newer filing (2026-05-07) specifies forward-looking statements relate to 'our Annual Report on Form 10-K for our fiscal year ended December 31, 2025' filed March 5, 2026
- Removed:
- Removed from newer filing (2026-05-07): final bullet point in forward-looking statements list stating 'other risks and uncertainties, including those listed under the section titled "Risk Factors."'
- Removed from newer filing (2026-05-07): disclosure stating 'While we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. Investors should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.'
- Removed from newer filing (2026-05-07): 'SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS' section and its content including bullet points about funding needs and product development prioritization
- Removed from newer filing (2026-05-07): statement 'If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. Investors should read this Quarterly Report on Form 10-Q, the documents that we reference in this Quarterly Report on Form 10-Q and the other documents that we file with the Securities and Exchange Commission ("SEC"), with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.'
- Reworded:
- Newer filing (2026-05-07) changes last bullet point from 'our ability to maintain adequate internal controls over financial reporting and to manage the business of the Company in accordance with applicable laws and the highly regulated industry in which we participate; and' to 'our ability to maintain adequate internal controls over financial reporting and to manage our business in accordance with applicable laws and the highly regulated industry in which we participate.'
- Newer filing (2026-05-07) removes '; and' from end of final bullet point and removes subsequent bullet point about 'other risks and uncertainties'
- Older filing (2025-12-11) states 'Factors that may cause actual results to differ materially from those implied or projected by forward-looking statements include, among other things, those listed under the section titled "Risk Factors" and elsewhere in this Quarterly Report on Form 10-Q.' while newer filing (2026-05-07) states 'Factors that may cause actual results to differ materially from those implied or projected by forward-looking statements include, among other things, those listed under the section titled "Risk Factors" in Part I, Item 1A in our Annual Report on Form 10-K for our fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission, or SEC, on March 5, 2026.'
- Notes:
- The newer filing text appears truncated and does not include the full Risk Factors section content itself, only header materials and forward-looking statements disclosure
- The older filing text also appears truncated at the end of the 'SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS' section
- Financial statements and condensed consolidated statements of operations appear in newer filing but not in older filing excerpt provided, making full comparison of those sections not possible
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
2 open-market purchases and 9 open-market sales by insiders in the last 90 days.
- Last 90 days2 buys ($146260) · 9 sells ($2M) — 2 buying, 6 selling insiders
- Last 180 days2 buys ($146260) · 9 sells ($2M) — 2 buying, 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-08. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about EVMN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding EVMN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 854,801
- Reported value $19,651,875
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 2 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
EVMN had 4,481,198 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
EVMN had 12.3% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.67 days to cover at the same settlement.
- Reported short interest (shares) 4,481,198
- Short interest (% of shares outstanding) 12.3%
- Prior settlement (shares) 4,017,562
- Reported change 11.54%
- Days to cover (reported) 8.67
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
EVOMMUNE INC is found in…
Frequently asked questions
What does EVOMMUNE INC (EVMN) do?
Evommune is an early-stage clinical-stage biotechnology company developing immunology-focused product candidates. The company's lead programs include EVO756 and EVO301, which are currently in clinical development. Evommune is unprofitable and pre-revenue, requiring additional funding to advance its product candidates toward regulatory approval and potential commercialization.
What sector is EVOMMUNE INC (EVMN) in?
EVOMMUNE INC (EVMN) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceutical / immunology. It trades on NYSE.
Is EVOMMUNE INC (EVMN) overbought or oversold right now?
EVOMMUNE INC (EVMN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 51, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EVMN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.